AbbVie Inc. Share Price

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 01:30:02 14/06/2024 am IST 5-day change 1st Jan Change
166.6 USD +0.28% Intraday chart for AbbVie Inc. -1.19% +7.48%
Sales 2024 * 55.18B 4,609B Sales 2025 * 58.14B 4,856B Capitalization 294B 24,568B
Net income 2024 * 7.74B 646B Net income 2025 * 10.56B 882B EV / Sales 2024 * 6.36 x
Net Debt 2024 * 56.89B 4,752B Net Debt 2025 * 47.91B 4,002B EV / Sales 2025 * 5.88 x
P/E ratio 2024 *
31.2 x
P/E ratio 2025 *
24.3 x
Employees 50,000
Yield 2024 *
3.74%
Yield 2025 *
3.9%
Free-Float 96.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.04%
1 week-1.19%
Current month+3.30%
1 month+3.27%
3 months-7.39%
6 months+7.95%
Current year+7.48%
More quotes
1 week
165.00
Extreme 165
170.75
1 month
153.58
Extreme 153.58
170.75
Current year
153.58
Extreme 153.58
182.89
1 year
130.96
Extreme 130.9601
182.89
3 years
105.56
Extreme 105.56
182.89
5 years
62.55
Extreme 62.55
182.89
10 years
45.45
Extreme 45.45
182.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 01/13/01
Director of Finance/CFO 57 01/13/01
President 53 01/12/01
Members of the board TitleAgeSince
Director/Board Member 63 01/13/01
Director/Board Member 66 01/13/01
Director/Board Member 70 01/13/01
More insiders
Date Price Change Volume
13/24/13 166.6 +0.28% 3,690,768
12/24/12 166.1 -0.96% 4,725,634
11/24/11 167.7 -1.62% 3,790,165
10/24/10 170.5 +0.61% 4,247,645
07/24/07 169.4 +0.50% 3,781,858

Delayed Quote Nyse, June 14, 2024 at 01:30 am IST

More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
166.6 USD
Average target price
183 USD
Spread / Average Target
+9.90%
Consensus